DivcoWest said Monday that Collegium Pharmaceutical has signed a headquarters lease for 40,288 square feet on floors 11 and 12 at One Lincoln in Boston’s Financial District, relocating from suburban Stoughton, MA. Slated for the first quarter of 2027, Collegium’s arrival adds a life science presence to a tenant roster that already spans several industries at the 36-story, 1.1-million-square-foot office tower, which underwent a redevelopment in 2025.

“This relocation reflects a broader trend we’re seeing across Greater Boston,” said Justin Dziama, principal at Avison Young, who represented Collegium with colleague Connor Hayes. “As market conditions have shifted, companies are taking advantage of the opportunity to upgrade their workplace experience, improve accessibility for employees and establish a stronger presence in the urban core. For Collegium, One Lincoln provided the chance to accomplish all of those goals in one move.”

Added Newmark executive managing director Gil Dailey, “Collegium’s lease underscores the momentum behind One Lincoln and the continued demand for well-located, highly activated office environments.” Dailey and Newmark executive managing director Dave Martel represented DivcoWest.

The post Collegium Pharmaceutical Signs with DivcoWest in Boston’s Financial District appeared first on Connect CRE.

​